ArticleMikrochimica acta2026
Multifunctional fluorescent probe for dual monitoring of polarity and HOCl to visualize ferroptosis‑mediated drug‑induced liver injury.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Ferroptosis is a recently characterized, iron-dependent modality of regulated cell death that precipitates organ injury by derailing cellular redox homeostasis and can serve as an indicator of hepatic injury severity. Yet studies linking ferroptosis to liver pathology face two major constraints: (1) fluorescent probes that use iron ions as the analyte suffer interference from specific reaction chemistries, resulting in low sensitivity and poor physiological stability; and (2) the therapeutic promise of modulating ferroptosis in liver injury remains underexplored. To overcome these barriers, this study introduces two non–iron-based biomarkers—lipid droplet polarity and hypochlorous acid-as alternative analytical targets, thereby avoiding the limitations imposed by iron-specific reactions. Accordingly, we engineered NIR-MZY, a dual-responsive probe capable of simultaneously monitoring lipid droplet polarity and hypochlorous acid, thereby assessing the potential of ferroptosis-targeted strategies for the treatment of liver injury. As expected, we tracked dynamic changes in lipid droplet polarity and hypochlorous acid (HOCl) during drug-induced liver injury and visualized their modulation in cellular and zebrafish models under ferroptosis induction and inhibition. These results indicate that manipulating ferroptosis attenuates hepatic damage and substantiate its viability as a therapeutic target. Thus, NIR-MZY emerges as a convenient, sensitive imaging modality that enables precise diagnosis and intervention in ferroptosis-driven liver injury.
Indexed as
Identifiers
41824106What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.